BioSpace News Archive

GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary financial results for the quarter ended September 30, 2020. Third Quarter 2020 Highlights Placed net 70 ePlex ® analyzers, finishing the quarter with a global installed base of more than 720 ePlex analyzers, an increase of 47% versus the third quarter of 2019 Total revenue expected to

Application of ImmTOR™ plus IGAN’s IgA p rotease to target immunoglobulin A ( IgA ) deposition, the critical event leading to IgA N ephropathy ( IgAN ) Selecta’s IgA nephropathy program builds upon SEL-212 , which has demonstrated ImmTOR™ e ffective at tolerizing a highly immunogenic therapeutic enzyme Investigational New Drug (IND) application expected in Q4 2021 WATERTOWN, Mass., and BOSTON, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences

RP2 Panel at a Glance GenMark’s ePlex ® Respiratory Pathogen Panel 2 (RP2 Panel) has received Emergency Use Authorization from the FDA. The RP2 Panel provides results in less than two hours for more than 20 viruses and bacteria that cause common respiratory infections with similar symptoms, including COVID-19, flu, bronchitis and the common cold. The rapid, multiplex molecular testing offered by the RP2 Panel will be vital in preparing for the fall and winter, when COVID-19 will be cir

Ali Behbahani, M.D. takes on role of Chairperson of the Board Michael G. Atieh joins the Board of Directors as Chair person of the Audit Committee PRINCETON, N.J., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced changes to its Board of Directors, consisten

Viracta Therapeutics, Inc. (the “Company”), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston , MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the Solebury Trout Fall Private Company Showcase on Thursday, October 15, 2020 at 1:00 pm ET

KB301 is designed to deliver a full-length human type 3 collagen transgene via injection - The Phase 1 PEARL-1 clinical study to evaluate KB301 in acne scars and fine wrinkles is currently enrolling PITTSBURGH--( BUSINESS WIRE )-- Krystal Biotech , Inc. (Nasdaq:KRYS) today announced the presentation of positive preclinical data supporting the ongoing development of KB301, an innovative, investigational therapy designed to reverse the decli

Willow Biosciences Inc. is pleased to announce that it has agreed to partner with researchers at the University of Lethbridge and the University of Calgary to study the therapeutic potential of non-psychoactive cannabinoids in relation to intestinal inflammation, abdominal pain and depression.

Achieve Life Sciences, Inc. announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually October 13th - 16th, 2020.

A study in Nature Immunology found that nicotinamide riboside (NR) improved the anti-cancer function of tumor infiltrating immune T-cells in mice

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, announced an amendment to its existing debt facility with CRG Servicing LLC.